Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.

Antimicrobial Agents and Chemotherapy
M ArendrupW W Hope

Abstract

We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half- and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E(50)s) were 194.2 and 53.99 mg · h/liter, respectively. In contrast, the maximum effect (E(max)) for caspofungin was higher against S3 than R83, but the estimates for E(50) were similar (187.1 and 203.5 mg · h/liter, respectively). Anidulafungin failed to induce a ≥...Continue Reading

References

Jan 1, 1983·Chemotherapy·N Frimodt-MøllerV Frølund Thomsen
Feb 19, 2002·Antimicrobial Agents and Chemotherapy·Julie A StoneScott A Waldman
Feb 9, 2006·The Journal of Antimicrobial Chemotherapy·Michel LaverdièreDavid S Perlin
Mar 3, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mikkel Krogh-MadsenJenny Dahl Knudsen
May 24, 2006·Pharmacotherapy·Christopher D MillerDavid S Perlin
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Santosh KatiyarThomas Edlind
Jan 16, 2007·Clinical Microbiology Reviews·M A Pfaller, D J Diekema
Feb 3, 2007·Journal of Clinical Microbiology·Anna Brillowska-DabrowskaMaiken Cavling Arendrup
May 1, 2007·The Journal of Antimicrobial Chemotherapy·Marie-Thérèse BaixenchEric Dannaoui
May 8, 2007·Lancet·Ernst-Rüdiger KuseUNKNOWN Micafungin Invasive Candidiasis Working Group
May 23, 2007·Expert Opinion on Pharmacotherapy·Nathan P Wiederhold, James S Lewis
Jun 15, 2007·The New England Journal of Medicine·Annette C ReboliUNKNOWN Anidulafungin Study Group
Jun 16, 2007·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·David S Perlin
Sep 7, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasDonald N Buell
Nov 21, 2007·The Journal of Antimicrobial Chemotherapy·Tim PasqualeHector Bonilla
Jan 15, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility T
Apr 2, 2008·Antimicrobial Agents and Chemotherapy·John D ClearyDavid S Perlin
Sep 17, 2008·Antimicrobial Agents and Chemotherapy·Guillermo Garcia-EffronDavid S Perlin
Feb 5, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasUNKNOWN Infectious Diseases Society of America
Apr 7, 2010·Antimicrobial Agents and Chemotherapy·Mariana CastanheiraMichael A Pfaller
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·D AndesA Lepak
Apr 28, 2010·Journal of Clinical Microbiology·Christopher D PfeifferBarbara D Alexander
Aug 17, 2010·Current Opinion in Critical Care·Maiken C Arendrup
Nov 6, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·M A PfallerUNKNOWN CLSI Subcommittee for Antifungal Susceptibility Testing
Apr 20, 2011·Antimicrobial Agents and Chemotherapy·Nathan P WiederholdThomas F Patterson
Jul 1, 2011·Journal of Clinical Microbiology·Maiken Cavling ArendrupHelle Krogh Johansen
Jul 28, 2011·The Journal of Infectious Diseases·Ronen Ben-AmiDimitrios P Kontoyiannis

❮ Previous
Next ❯

Citations

Oct 19, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·U Theuretzbacher
Mar 15, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Barbara D AlexanderMichael A Pfaller
Mar 15, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis Ostrosky-Zeichner
Nov 20, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C F RodriguesM Henriques
Jun 1, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nicholas D BeydaKevin W Garey
Oct 16, 2013·Antimicrobial Agents and Chemotherapy·Mariana CastanheiraMichael A Pfaller
Jan 16, 2013·Biotechnology Advances·Santi M MandalOctavio L Franco
Jan 8, 2016·Infectious Disease Clinics of North America·Mohammad T AlbatainehNathan P Wiederhold
Jul 21, 2015·Annals of the New York Academy of Sciences·David S Perlin
Jan 15, 2014·Mycoses·Maiken Cavling ArendrupUNKNOWN European Committee on Antimicrobial Susceptibility Testing - Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
Nov 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David S Perlin
Aug 19, 2014·International Journal of Antimicrobial Agents·Mariana CastanheiraMichael A Pfaller
Mar 29, 2014·Diagnostic Microbiology and Infectious Disease·Eiyu MatsumotoDaniel Diekema
Mar 13, 2014·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Maiken C ArendrupWilliam W Hope
Apr 30, 2013·Bioorganic & Medicinal Chemistry Letters·Sheo B SinghMary Motyl
Oct 25, 2016·Current Infectious Disease Reports·Nathan P Wiederhold
Feb 9, 2017·The Journal of Antimicrobial Chemotherapy·Laura Judith Marcos-ZambranoJesús Guinea
May 2, 2018·Antimicrobial Agents and Chemotherapy·María Ángeles Bordallo-CardonaJesús Guinea
Jan 10, 2018·Antimicrobial Agents and Chemotherapy·María Ángeles Bordallo-CardonaJesús Guinea
Nov 23, 2016·Antimicrobial Agents and Chemotherapy·María Ángeles Bordallo-CardonaJesús Guinea
Aug 30, 2017·Antimicrobial Agents and Chemotherapy·Hamed FakhimHamid Badali
Sep 24, 2015·Antimicrobial Agents and Chemotherapy·Ryan K ShieldsCornelius J Clancy
Mar 30, 2016·Antimicrobial Agents and Chemotherapy·Laura Judith Marcos-ZambranoJesús Guinea
Apr 2, 2014·Antimicrobial Agents and Chemotherapy·Rasmus Hare JensenMaiken Cavling Arendrup
Oct 31, 2018·Antimicrobial Agents and Chemotherapy·Ryan K ShieldsCornelius J Clancy
Jan 30, 2019·Journal of Clinical Medicine·Célia F RodriguesMariana Henriques
May 12, 2018·Nature Reviews. Disease Primers·Peter G PappasBart Jan Kullberg
Jul 10, 2019·Antimicrobial Agents and Chemotherapy·Maiken Cavling ArendrupOscar Zaragoza

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.